产前DNA定序市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球产前DNA定序市场预计将从2025年的26.1亿美元成长到2031年的38.9亿美元，复合年增长率为6.88%。

该市场专注于分析母体血液中存在的胎儿遗传物质，以检测染色体异常和某些遗传疾病。这主要是由于临床上越来越倾向于选择非侵入性检测而非羊膜穿刺等高风险检测，以及随着孕妇年龄增长，对准确评估的需求也效用增加。国际产前诊断学会报告称，到2024年，在随机选择的、经超音波检查发现异常的妊娠病例中，产前外EXOME定序的诊断率将达到31%，这凸显了推动这一需求的临床实用性。

然而，由于先进定序检测高成本且报销政策不统一，市场面临许多障碍。许多医疗系统和保险公司仅对高风险怀孕提供全额报销，这造成了经济障碍，限制了普通低风险族群使用这些基因组技术。这种经济摩擦阻碍了市场扩张，也使得所有孕妇，无论其风险状况如何，都无法普遍获得这些先进的诊断工具。

市场驱动因素

随着医疗机构和孕妇优先选择更安全、更准确的筛检方式以避免羊膜穿刺术带来的流产风险，从传统侵入性方法向非侵入性产前检测 (NIPT) 的快速转变正在推动市场显着增长。检测量的显着增长印证了这一趋势；例如，Natera 在其 2025 年第一季财报中宣布，该公司已完成约 855,100 例检测，较去年同期增长 16.2%，凸显了 NIPT 正在成为主流诊疗标准。

次世代定序(NGS) 和生物资讯学领域的技术突破正在进一步加速这一成长。诸如单分子计数等创新技术使得更早期、更全面的胎儿评估成为可能。 2025 年 5 月，Myriad Genetics 宣布其产前检测收入年增 11%，部分原因是其「Prequel 早期妊娠年龄」检测的推出。此外，BillionToOne 于 2025 年 11 月进行的首次股票公开发行(IPO) 筹集了约 2.73 亿美元，进一步证实了该行业强劲的投资吸引力。

市场挑战

全球产前DNA定序市场成长的主要障碍是先进定定序检测的高昂费用以及不均衡的报销政策。儘管临床上越来越多地采用无创技术，但高昂的价格使其难以成为低风险族群的标准治疗方案。支付方往往认为这些评估仅在高风险妊娠中才具有医学必要性，导致患者自付费用显着增加，并限制了检测量和收入潜力。

这些严重的健保覆盖缺口极大地限制了潜在市场。例如，根据产前筛检普及联盟2024年3月发布的报告，美国有四个州的医疗筛检计划不为任何孕妇提供非侵入性产前筛检，无论其风险如何。这些零散的政策迫使基因组学公司在有限的市场范围内运营，直接阻碍了其规模化发展，并导致其普及率停滞不前。

市场趋势

市场的一个根本性转变是非侵入性产前检测 (NIPT) 的应用范围从标准的染色体异常筛检扩展到包括微缺失和单基因疾病，可以直接从母体血液中检测出囊肿纤维化等疾病。 BillionToOne 公司在 2025 年 1 月发布的一份报告中强调了对这种全面、无风险评估的需求，该报告预测，该公司 2024 年的收入将达到 1.53 亿美元，主要得益于其单基因产前检测业务，该业务预计将占据美国市场 15% 的份额。

同时，第三代长读长定序技术的应用使得短读长定序技术难以检测到的结构突变和重复序列扩增成为可能，从而提高了超音波检查发现异常怀孕的诊断准确率。为了佐证这一趋势，牛津奈米孔技术公司于2025年9月发布报告称，其临床市场部门上半年的收入增长了52.9%，显示基于奈米孔的定序技术在临床诊断中的效用正在迅速扩展。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球产前DNA定序市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（遗传性疾病、非遗传性疾病）
  • 依应用领域（血友病、唐氏症、囊肿纤维化、自闭症等）
  • 依最终用户（医院/诊所、製药/生技公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美产前DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲产前DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区产前DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲产前DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲产前DNA定序市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球产前DNA定序市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies Inc
• BGI Group
• F. Hoffmann-La Roche ltd
• Illumina Inc
• Laboratory Corporation of America Holdings
• Natera Inc
• Genomic Health Inc
• Myriad Genetics Inc
• PerkinElmer Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Prenatal DNA Sequencing Market is projected to expand from USD 2.61 Billion in 2025 to USD 3.89 Billion by 2031, reflecting a compound annual growth rate of 6.88%. This market focuses on analyzing fetal genetic material found in maternal blood to detect chromosomal aneuploidies and specific genetic disorders, driven by a growing clinical preference for non-invasive testing over riskier procedures like amniocentesis and the need for accurate evaluations due to rising maternal ages. Highlighting the clinical utility fueling this demand, the International Society for Prenatal Diagnosis reported in 2024 that prenatal exome sequencing achieved a diagnostic yield of 31 percent for unselected pregnancies presenting with sonographically detected anomalies.

However, the market faces hurdles due to the high costs of advanced sequencing tests and inconsistent reimbursement landscape. Many healthcare systems and insurers limit full coverage to high-risk pregnancies, creating financial barriers that restrict the adoption of these genomic technologies among the general low-risk population. This economic friction impedes broader market expansion, preventing these advanced diagnostic tools from becoming universally accessible to all expectant parents regardless of their risk profile.

Market Driver

The market is expanding significantly due to the rapid shift toward Non-Invasive Prenatal Testing (NIPT) over traditional invasive methods, as healthcare providers and expectant parents prioritize safer, high-accuracy screening options to avoid the miscarriage risks associated with amniocentesis. This trend is evidenced by substantial growth in test volumes; for example, Natera reported in its First Quarter 2025 Financial Results that it processed approximately 855,100 tests, marking a 16.2 percent increase compared to the same period the previous year, underscoring the transition of NIPT into a mainstream standard of care.

Growth is further accelerated by technological breakthroughs in Next-Generation Sequencing (NGS) and bioinformatics, which are enabling earlier and more comprehensive fetal assessments through innovations such as single-molecule counting. Myriad Genetics noted in May 2025 that its prenatal testing revenue increased by 11 percent year-over-year, driven partly by the adoption of its Prequel Early Gestational Age test, while the sector's robust investment appeal was validated by BillionToOne's initial public offering in November 2025, which raised approximately 273 million dollars.

Market Challenge

A primary obstacle restricting the growth of the Global Prenatal DNA Sequencing Market is the prohibitive cost of advanced sequencing tests combined with uneven reimbursement policies. Despite the clinical shift toward non-invasive methods, high price points prevent these tools from becoming standard care for the low-risk population, as payers often view these evaluations as medically necessary only for high-risk pregnancies, resulting in significant out-of-pocket expenses that limit test volume and revenue potential.

The severity of these coverage gaps significantly constrains the addressable market, as illustrated by the Coalition for Access to Prenatal Screening, which reported in March 2024 that four state Medicaid programs in the United States provided zero reimbursement for non-invasive prenatal screening for any pregnant individual, regardless of risk. Such fragmented policies force genomic companies to operate within a limited market scope, directly hampering their ability to scale operations and leading to stagnated adoption rates.

Market Trends

A fundamental shift in the market is the expansion of Non-Invasive Prenatal Testing (NIPT) to encompass microdeletions and monogenic disorders, moving beyond standard aneuploidy screening to detect conditions like cystic fibrosis directly from maternal blood. This demand for comprehensive, risk-free assessment is highlighted by BillionToOne's report in January 2025, which stated that the company's revenue reached 153 million dollars in 2024, largely fueled by its single-gene prenatal testing business capturing an estimated 15 percent share of the U.S. market.

Simultaneously, the integration of third-generation long-read sequencing is revolutionizing the detection of structural variants and repeat expansions that short-read technologies often miss, offering improved diagnostic yields for pregnancies with ultrasound abnormalities. Underscoring this trend, Oxford Nanopore Technologies reported in September 2025 that revenue from its Clinical market segment increased by 52.9 percent during the first half of the year, demonstrating the rapidly growing utility of nanopore-based sequencing in clinical diagnostics.

Key Market Players

• Agilent Technologies Inc
• BGI Group
• F. Hoffmann-La Roche ltd
• Illumina Inc
• Laboratory Corporation of America Holdings
• Natera Inc
• Genomic Health Inc
• Myriad Genetics Inc
• PerkinElmer Inc

Report Scope

In this report, the Global Prenatal DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prenatal DNA Sequencing Market, By Type

• Genetic Diseases
• Nonhereditary Diseases

Prenatal DNA Sequencing Market, By Application

• Hemophilia
• Down Syndrome
• Cystic Fibrosis
• Autism
• Others

Prenatal DNA Sequencing Market, By End user

• Hospitals And Clinics
• Pharmaceutical And Biotechnology Companies
• Others

Prenatal DNA Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prenatal DNA Sequencing Market.

Available Customizations:

Global Prenatal DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prenatal DNA Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Genetic Diseases, Nonhereditary Diseases)
  • 5.2.2. By Application (Hemophilia, Down Syndrome, Cystic Fibrosis, Autism, Others)
  • 5.2.3. By End user (Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Prenatal DNA Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prenatal DNA Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Prenatal DNA Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Prenatal DNA Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End user

7. Europe Prenatal DNA Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prenatal DNA Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End user
  • 7.3.2. France Prenatal DNA Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Prenatal DNA Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Prenatal DNA Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Prenatal DNA Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End user

8. Asia Pacific Prenatal DNA Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prenatal DNA Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End user
  • 8.3.2. India Prenatal DNA Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Prenatal DNA Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Prenatal DNA Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Prenatal DNA Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End user

9. Middle East & Africa Prenatal DNA Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prenatal DNA Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Prenatal DNA Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Prenatal DNA Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End user

10. South America Prenatal DNA Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prenatal DNA Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Prenatal DNA Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Prenatal DNA Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prenatal DNA Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BGI Group
• 15.3. F. Hoffmann-La Roche ltd
• 15.4. Illumina Inc
• 15.5. Laboratory Corporation of America Holdings
• 15.6. Natera Inc
• 15.7. Genomic Health Inc
• 15.8. Myriad Genetics Inc
• 15.9. PerkinElmer Inc

16. Strategic Recommendations

17. About Us & Disclaimer